![4-[6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-ca…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fcas-image%2Fthumb-webp%2F399977-4-6-methoxy-7-3-piperidin-1-ylpropoxy-quinazolin-4-yl-n-4-propan-2-yloxyphenyl-piperazine-1-carboxamide.webp&w=3840&q=75)
CAS 387867-13-2: 4-[6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide
Formula:C31H42N6O4
InChI:InChI=1/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)
InChI key:InChIKey=UXXQOJXBIDBUAC-UHFFFAOYSA-N
SMILES:CC(C)Oc1ccc(cc1)NC(=O)N1CCN(CC1)c1c2cc(c(cc2ncn1)OCCCN1CCCCC1)OC
Synonyms:- (4-(6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-N-(4-(methylethoxy)phenyl)carboxamide
- 1-Piperazinecarboxamide, 4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-
- 4-[6-Methoxy-7-[3-(1-piperidinyl)propoxy]-4-quinazolinyl]-N-[4-(1-methylethoxy)phenyl]-1-piperazinecarboxamide
- 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-[4-(1-methylethoxy)phenyl]piperazine-1-carboxamide
- Ct 53518
- Mln 0518
- Mln 518
- Tandutinib
- Tandutinib(TINIBS)
Sort by
Found 7 products.
Tandutinib
CAS:Tyrosine kinase inhibitor; antineoplastic activity; pro-apoptoticFormula:C31H42N6O4Purity:Min. 95%Color and Shape:PowderMolecular weight:562.7 g/molTandutinib
CAS:Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3Formula:C31H42N6O4Purity:99.45% - ≥98%Color and Shape:White SolidMolecular weight:562.7Tandutinib
CAS:Controlled ProductApplications An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) and other cancer indications. The drug exhibited limited activity as a single agent in phase I and II clinical trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML when administered in combination with cytarabine and daunorubicin. References Manning, G., et al.: Science, 298, 1912 (2002), Lombardo, L., et al.: J. Med. Chem., 47, 6658 (2004), Knight, Z., et al.: Chem. Biol., 12, 621 (2005), Baselga, J., et al.: Science, 312, 1175 (2006), Garber, K., et al.: Nat. Biotechnol., 24, 127 (2006), Flaherty, K., et al.: Clin. Cancer Res., 13, 747 (2007),Formula:C31H42N6O4Color and Shape:NeatMolecular weight:562.70N-(4-Isopropoxyphenyl)-4-(6-Methoxy-7-(3-(Piperidin-1-Yl)Propoxy)Quinazolin-4-Yl)Piperazine-1-Carboxamide
CAS:N-(4-Isopropoxyphenyl)-4-(6-Methoxy-7-(3-(Piperidin-1-Yl)Propoxy)Quinazolin-4-Yl)Piperazine-1-CarboxamidePurity:98%Molecular weight:562.7g/mol
